Advertisement

Search Results

Advertisement



Your search for The,The matches 30870 pages

Showing 101 - 150


lung cancer

Does Prediagnosis Smoking Cessation Improve Overall Survival in Patients With NSCLC?

In a cohort study reported in JAMA Network Open, Wang et al found that overall survival in patients with non–small cell lung cancer (NSCLC) who stopped smoking prior to their cancer diagnosis was better than overall survival among those who were current smokers at the time of their diagnosis. Study ...

hepatobiliary cancer
lung cancer
issues in oncology

Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds

Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...

gynecologic cancers
issues in oncology

Patients With Cervical Cancer May Be at Higher Risk for Urinary Tract Infections After Radical Hysterectomies

Patients with early-stage cervical cancer may have an increased risk of developing catheter-associated urinary tract infections following radical hysterectomies if they had a history of smoking or used catheters for more than 7 days postsurgery, according to a new study by Mercadel et al in the...

gynecologic cancers
issues in oncology

HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients

Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...

cns cancers
immunotherapy

Combined Delivery of DNX-2401 Plus Pembrolizumab May Be Safe and Effective in Patients With Recurrent Glioblastoma

Intratumoral delivery of the engineered oncolytic virus DNX-2401 in combination with subsequent immunotherapy with pembrolizumab may be safe and effective at improving survival outcomes in patients with recurrent glioblastoma, according to a study published by Nassiri et al in Nature Medicine....

bladder cancer
genomics/genetics
immunotherapy

Phase II Trial of Guadecitabine Plus Atezolizumab in Patients With Metastatic Bladder Cancer

Although hypomethylating agents previously appeared to be a promising treatment option for patients with bladder cancer refractory to immunotherapy, researchers were forced to halt a recent phase II clinical trial after patients experienced either no response to treatment or rapid tumor...

immunotherapy

Immune Checkpoint Inhibitors Show Promise for People Living With HIV

New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published by El Zarif et al in the Journal of Clinical Oncology. The...

colorectal cancer
immunotherapy

Addition of Bevacizumab to Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer

As reported in The New England Journal of Medicine by Prager et al, the phase III SUNLIGHT trial has shown prolonged overall survival with the addition of bevacizumab to trifluridine/tipiracil (FTD-TPI) in previously treated patients with metastatic colorectal cancer. As stated by the...

breast cancer
colorectal cancer
prostate cancer
genomics/genetics

Potential Utility of Polygenic Risk Scores in Cancer Screening in the United Kingdom

In a modeling study reported in The Lancet Oncology, Huntley et al found that the extension of UK cancer screening programs for breast, prostate, and colorectal cancers to a polygenic risk score (PRS)-defined high-risk group of patients with cancer may improve cancer case detection and avoidance of ...

solid tumors
supportive care
covid-19

Patients With Cancer May Prefer Telemedicine Appointments Over In-Person Visits When Both Are Available

Investigators have found that telemedicine may consistently outperform in-person visits for cancer care when assessed for access to care, provider response, and patient experience, according to a new study published by Patel et al in JNCCN–Journal of the National Comprehensive Cancer Network....

hepatobiliary cancer
issues in oncology

Immigrant Adults With Hepatocellular Carcinoma May Have Higher Survival Rates Than Those Born in the United States

Immigrant adult patients who have hepatocellular carcinoma and reside in the United States may have higher rates of survival compared with those who have the disease and were born in the United States, according to a new study published by Zhou et al in the Journal of the National Cancer Institute. ...

breast cancer

Long-Term Risk Prediction for Invasive Breast Cancer: AI System Plus Volumetric Density on Screening Mammography

In a study reported in the Journal of Clinical Oncology, Vachon et al found that the combination of an artificial intelligence (AI) imaging algorithm, together with measures of breast density on mammography screening, were capable of long-term prediction of risk of invasive breast cancer. As stated ...

solid tumors
hematologic malignancies
genomics/genetics

Familial Clonal Hematopoiesis in Individuals With a Mutation in Telomere-Related Gene POT1

In a study reported in The New England Journal of Medicine, DeBoy et al found that individuals carrying germline heterozygous loss-of-function mutations in the telomere-related gene POT1 had long telomeres and may be at risk for benign and malignant neoplasms as part of a familial clonal...

prostate cancer

Patient-Reported Outcomes From the NRG Oncology/RTOG 0815 in Intermediate-Risk Prostate Cancer

In an analysis of the phase III NRG Oncology/RTOG 0815 study reported in the Journal of Clinical Oncology, Benjamin Movsas, MD, and colleagues found few differences in patient-reported outcomes among patients with intermediate-risk prostate cancer receiving short-term total androgen suppression...

prostate cancer

Addition of Short-Term ADT to Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer

As reported in the Journal of Clinical Oncology by Daniel J. Krauss, MD, and colleagues, the phase III NRG Oncology/RTOG 0815 study showed no significant improvement in overall survival with the addition of short-term androgen-deprivation therapy (ADT) to dose-escalated radiotherapy in patients...

President Biden Announces Intent to Nominate Monica M. Bertagnolli, MD, as Director of the NIH

In a statement released by The White House on May 15, President Joe Biden announced his intent to nominate Monica M. Bertagnolli, MD, as Director of the National Institutes of Health (NIH), the world’s preeminent biomedical research organization. As the statement makes clear, Dr. Bertagnolli is a...

issues in oncology
solid tumors

Young Native Hawaiians and Pacific Islanders May Face Highest Rates of Cancer Mortality

Investigators have found that young Native Hawaiian and Pacific Islander patients may experience the highest rates of cancer mortality of any racial group in the United States among those aged 20 to 49 years. The new data were published by Haque et al in the Journal of the National Cancer...

kidney cancer
immunotherapy

Cabozantinib in Combination With Nivolumab and Ipilimumab May Slow Progression of Advanced Renal Cell Carcinoma

The targeted kinase inhibitor cabozantinib plus a two-drug immunotherapy combination of nivolumab and ipilimumab may be capable of slowing cancer progression in patients with advanced renal cell carcinoma who received no prior lines of therapy, according to a study published by Choueiri et al in...

lymphoma

Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients With PTCL-TFH

Researchers have found that azacitidine may be capable of increasing the effectiveness of chemotherapy and aiding nearly 90% of patients who had peripheral T-cell lymphoma with the T follicular helper cell phenotype (PTCL-TFH) achieve remission, according to a novel study published by Ruan et al in ...

leukemia

Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab in Previously Untreated Patients With CLL

As reported in The Lancet Oncology by Peter Hillmen, MBChB, PhD, and colleagues, an interim analysis of the UK phase III FLAIR trial has shown significantly improved progression-free survival with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated...

breast cancer

Interruption of Adjuvant Endocrine Therapy to Attempt Pregnancy in Women With Breast Cancer

In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with an increased short-term risk of breast cancer events among women with hormone...

hematologic malignancies

Ruxolitinib for Patients With Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide

In a UK phase II trial (MAJIC-PV) reported in the Journal of Clinical Oncology, Harrison et al found that ruxolitinib produced a higher complete response rate vs best available therapy in patients with polycythemia vera intolerant of or resistant to hydroxycarbamide. Study Details In the...

cns cancers

Lenalidomide in Previously Treated Children With Low-Grade Gliomas

In a Children’s Oncology Group phase II trial reported in the Journal of Clinical Oncology, Katherine E. Warren, MD, and colleagues found that lenalidomide showed activity in children with pilocytic astrocytomas and optic pathway gliomas who did not respond to initial therapy. As noted by the...

breast cancer

Longitudinal Change in Mammographic Breast Density and Risk of Breast Cancer

In a study reported in JAMA Oncology, Jiang et al found that breast density decreased over time among patients undergoing mammographic screening for breast cancer, but that the decrease was smaller in the affected breast among patients who developed breast cancer vs the decrease observed in...

prostate cancer

Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT

In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...

gynecologic cancers
issues in oncology

Racial Disparities in the Risk of Ovarian Cancer for Patients With Fibroids and Endometriosis

A case-control study published recently by Harris et al in Obstetrics & Gynecology evaluated associations between endometriosis, uterine leiomyomas, and ovarian cancer risk by race, as well as the impact of hysterectomy on these associations. The investigators found that hysterectomy may modify ...

multiple myeloma
hematologic malignancies

Novel Calculator May Identify Patients With Favorable-Prognosis Hematologic Cancers

Researchers have developed a calculator that may be capable of identifying patients who have multiple myeloma and light-chain amyloidosis with more benign profiles and, consequently, better prognoses, according to a novel study published by Burgos et al in the Journal of Clinical Oncology. The...

breast cancer
issues in oncology

New Breast Cancer Screening Guidelines Call for Earlier, More Intensive Screenings for Women at High Risk

Updated recommendations from the American College of Radiology encouraged all women—particularly Black women and Ashkenazi Jewish women—to undergo risk assessments at 25 years of age to determine whether they may need breast cancer screenings earlier than age 40, according to new guidelines...

gynecologic cancers

Prognostic Factors Associated With Survival in Platinum-Resistant Ovarian Cancer

Overall survival time was doubled in women with recurrent platinum-resistant ovarian cancer who have BRCA1/2 mutations, who were treated with PARP inhibitors, and whose tumors were homologous repair–deficient (HRD-test–positive), according to a study that examined prognostic factors for survival in ...

gynecologic cancers
immunotherapy

Novel Immunotherapy Combination Explored in Platinum-Resistant Ovarian Cancer

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with platinum-resistant or -refractory ovarian cancer, in the ongoing phase Ib C-800 study presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Bruno...

gynecologic cancers

ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer

Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...

gynecologic cancers

Expert Point of View: Carol Aghajanian, MD

Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, commented on the final analysis of NOVA for The ASCO Post. She highlighted the difficulty in truly measuring overall survival in recurrent ovarian cancer. Dr. Aghajanian also ...

gynecologic cancers

NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer

After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...

gynecologic cancers

Expert Point of View: Amanda Nickles Fader, MD

Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...

gynecologic cancers

GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer

In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...

Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH

Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...

gynecologic cancers

Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer

Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...

gynecologic cancers
issues in oncology

SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival

Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...

gynecologic cancers

Expert Point of View: Joshua G. Cohen, MD

Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...

gynecologic cancers

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...

Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD

“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...

gynecologic cancers

Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer

The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...

gynecologic cancers
immunotherapy

Highlights of the SGO 2023 Annual Meeting on Women’s Cancer

The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...

lung cancer

An Incidental Finding of Cancer Likely Saved My Life

Except for a ganglion cyst that had mysteriously popped up on the palm of my right hand in the winter of 2016, I appeared to be in excellent health. I had never had any serious illnesses in my then 55 years and rarely even got colds. If the annoying cyst hadn’t interfered with my normal daily...

City of Hope Appoints New Director and Chief Scientific Officer

City of Hope recently announced the appointment of John D. Carpten, PhD, as Director of the National Cancer Institute (NCI)-designated comprehensive cancer center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. Dr. Carpten will also hold the Irell &...

integrative oncology

Personalized Mind-Body Medicine in Integrative Oncology

Guest Editor’s Note: Substantial evidence supports the value of practices that focus on the interactions among the mind, body, and behavior for promoting health and well-being. In this article, Kavita K. Mishra, MD, MPH, summarizes a clinical model for personalized mind-body medicine in cancer care ...

issues in oncology
pain management

ED Visits Among Patients With Cancer: Three Main Messages

There are “three main messages” to be gleaned from a study about emergency department visits and unplanned hospitalizations among patients with cancer, the study’s lead author, Amir Alishahi Tabriz, MD, PhD, MPH, told The ASCO Post. Dr. Alishahi is Assistant Member, Department of Health Outcomes...

issues in oncology
pain management

Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain

Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...

hematologic malignancies
immunotherapy

Cancer Immunology and Immunotherapy: Principles and Practice

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of...

bladder cancer
immunotherapy

Enfortumab Vedotin-ejfv With Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

On April 3, 2023, enfortumab vedotin-ejfv with pembrolizumab was granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-con­taining chemotherapy.1,2 Enfortu­mab ­vedotin-ejfv is an antibody-drug conjugate targeting nectin 4....

Advertisement

Advertisement



Advertisement